openPR Logo
Press release

Age-related Vision Dysfunction Market Size is expected to grow by 2034, estimates DelveInsight

08-20-2024 08:59 AM CET | Health & Medicine

Press release from: DelveInsight Business Research LLP

Age-related Vision Dysfunction Market

Age-related Vision Dysfunction Market

DelveInsight's "Age-related Vision Dysfunction Market Insights, Epidemiology and Market Forecast - 2034" report delivers an in-depth understanding of Age-related Vision Dysfunction, historical and forecasted epidemiology as well as the Age-related Vision Dysfunction market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Explore the intricate details of the Age-related Vision Dysfunction Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Age-related Vision Dysfunction Market Forecast. Click here to stay ahead in healthcare innovation @ Age-related Vision Dysfunction Market Size- https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Age-related Vision Dysfunction Market Report
• As per DelveInsight estimates, the cases of presbyopia are the highest among all the considered etiologies of in the 7MM.
• The United States accounted for more than 35% of cases of Wet-Age-related Macular Degeneration in the 7MM.
• The United States accounted for the highest prevalent cases of Glaucoma in the year 2023.
• As per DelveInsight estimates, Japan accounted for 50% of total Diagnosed prevalent cases of Presbyopia in 2023.
• The leading Age-related Vision Dysfunction Companies such as Hoffman La Roche, MicroLine, AbbVie, Regenxbio, Novartis, Santen, Nicox Ophthalmics, Kodiak Sciences, Opthea Limited, Ocular Therapeutix, Orasis Pharmaceuticals, IVERIC bio, Alkeus Pharmaceuticals, Outlook Therapeutics, Sun Pharma Advanced Research Company Limited, and many others.
• Promising Age-related Vision Dysfunction Therapies such as bevacizumab, Rocklatan (Latanoprast; Netarsudil Dimesylate), Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl), Xelpros (Latanoprost Ophthalmic Emulsion), and others.

Delve deep into the Age-related Vision Dysfunction Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Age-related Vision Dysfunction Market Forecast. Click here to shape the future @ Age-related Vision Dysfunction Prevalence- https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Age-related Vision Dysfunction Overview
Age-related vision dysfunction refers to changes in vision that occur as a natural part of aging. These changes typically start around middle age and progress over time. Age-related Vision Dysfunction presents a significant challenge among the elderly population, with a staggering one in three individuals experiencing some form of vision-reducing eye disease by the age of 65.

Age-related Vision Dysfunction Epidemiology Segmentation
• Total Age-related Vision Dysfunction Prevalent Cases
• Total Age-related Vision Dysfunction Diagnosed Prevalent Cases
• Age-related Vision Dysfunction Type-specific Diagnosed Prevalent Cases
• Age-related Vision Dysfunction Severity-specific Diagnosed Prevalent Cases
• Total Age-related Vision Dysfunction Treatable Cases

Navigate the complexities of the Age-related Vision Dysfunction Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Age-related Vision Dysfunction Market Forecast. Click here to get more insights @ Age-related Vision Dysfunction Treatment Market- https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Age-related Vision Dysfunction Marketed Drugs

• VABYSMO: Genentech
VABYSMO (faricimab-svoa) is a prescription medicine, developed by Genentech, given by injection into the eye used to treat adults with neovascular (wet) Age-related macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. VABYSMO was first approved in the US by the FDA in January 2022, targets and inhibits two disease pathways that drive wet Age-related macular degeneration and diabetic macular edema and is now available in multiple countries, including Europe. In October 2023, Roche received a new indication approval by FDA for the use of VABYSMO to treat macular edema following retinal vein occlusion.
• LUCENTIS: Genentech
LUCENTIS (ranibizumab injection) is a prescription medicine, developed by Genentech for the treatment of patients with wet Age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, myopic choroidal neovascularization. In April 2017, FDA Approves Genentech's LUCENTIS (ranibizumab Injection) for Diabetic Retinopathy, the leading cause of blindness among working age adults in the United States. It was the first and only medicine FDA-approved to treat all forms of diabetic retinopathy and Granted Priority Review Designation by the FDA based on analysis of results from a National Institutes of Health (NIH)-funded collaborative group study.

Age-related Vision Dysfunction Emerging Drugs
• KSI-301 (tarcocimab tedromer): Kodiak Sciences Inc.
Kodiak Science's KSI-301 is a novel anti-Vascular endothelial growth factor biologic designed to rapidly inhibit Vascular endothelial growth factor and provide extended durability of action to reduce the burden of frequent anti-Vascular endothelial growth factor injections. Delivering potent and sustained vascular endothelial growth factor inhibition enables patient compliance, results in long-term efficacy, and improves visual acuity outcomes. The drug has recently completed its phase III study. The biologic is also in Phase III for Diabetic Macular Edema, Diabetic retinopathy, Tetinal Vein Occlusion, and Triplet Inhibitor for dry Age-related Macular Degeneration. KSI-301 is administered as an intravitreal injection and designed to provide sustained inhibition of vascular endothelial growth factor for up to 6 months.
• ONS-5010/LYTENAVA: Outlook Therapeutics
Outlook Therapeutics' ONS-5010/LYTENAVA is an investigational ophthalmic formulation of bevacizumab under development to be administered as an intravitreal injection for the treatment of wet Age-related Macular Degeneration and other retinal diseases. ONS-5010 is a full-length, humanized anti-Vascular endothelial growth factor recombinant monoclonal antibody (mAb) that inhibits vascular endothelial growth factor and associated angiogenic activity

Unlock insights into the Age-related Vision Dysfunction Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Age-related Vision Dysfunction Market Forecast. Click here @ Age-related Vision Dysfunction Market Drivers and Barriers- https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Age-related Vision Dysfunction Therapies and Companies
• AGN-190584 (Allergan [acquired by AbbVie])
• MicroLine/Pilocarpine Ophthalmic (Eyenovia)
• PresbiDrops/CSF-1 (Orasis Pharmaceuticals)
• Zimura/ Avacincaptad pegol (IVERIC Bio)
• ALK-001 (Alkeus Pharmaceuticals)
• ONS-5010/Lytenava/Bevacizumab-vikg (Outlook Therapeutics)
• KSI-301 (Kodiak Sciences)
• Faricimab (Roche)
• Abicipar (Allergan [acquired by AbbVie]/Molecular Partners)
• RGX-314 (Regenxbio)
• Beovu/RTH258/Brolucizumab (Novartis)
• STN1013001/DE-130A/Catioprost and latanoprost emulsion (Santen SAS)
• NCX 470 (Nicox Ophthalmics)
• OTX-TP/Travoprost ophthalmic insert (Ocular Therapeutix)
• PDP-716 (Sun Pharma Advanced Research Company Limited)
• OPT-302 (Opthea)
• Lumitin/Conbercept (Chengdu Kanghong Pharmaceuticals)
• AKST4290/Lazucirnon (Alkahest)
• GT005 (Gyroscope Therapeutics)
• ADVM-022 (Adverum Biotechnologies)
• Emixustat hydrochloride (Kubota Vision)
• KVD001 (KalVista Pharmaceuticals)
• Luminate/ALG-1001/Risuteganib (Allergo Opthalmics and Baush Health)
• GB-102 (Graybug Vision)
• Razuprotafib/AKB-9778 (Aerpio Pharmaceuticals)
• Nyxol/Phentolamine Mesylate (Ocuphire Pharma)
• STN1012600/DE-126 (Santen Pharmaceutical)

Age-related Vision Dysfunction Market Outlook
The Age-related Vision Dysfunction market outlook reflects a dynamic landscape characterized by a growing demand for innovative treatments and technologies to address the diverse needs of aging populations worldwide. With approximately one in three individuals experiencing some form of vision-reducing eye disease by the age of 65, the prevalence of conditions such as Age-related macular degeneration, glaucoma, cataracts, diabetic retinopathy, and refractive errors underscores the urgent need for effective therapeutic interventions.

Gain a strategic edge in the Age-related Vision Dysfunction Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Age-related Vision Dysfunction Market Forecast. Click here to lead in advancements @ Age-related Vision Dysfunction Clinical Trials Assessment- https://www.delveinsight.com/sample-request/age-related-vision-dysfunction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Age-related Vision Dysfunction Market Report
• Coverage- 7MM
• Age-related Vision Dysfunction Companies- Hoffman La Roche, MicroLine, AbbVie, Regenxbio, Novartis, Santen, Nicox Ophthalmics, Kodiak Sciences, Opthea Limited, Ocular Therapeutix, Orasis Pharmaceuticals, IVERIC bio, Alkeus Pharmaceuticals, Outlook Therapeutics, Sun Pharma Advanced Research Company Limited, and many others.
• Age-related Vision Dysfunction Therapies- bevacizumab, Rocklatan (Latanoprast; Netarsudil Dimesylate), Eybelis Ophthalmic Solution (DE-117, Omidenepag isopropyl), Xelpros (Latanoprost Ophthalmic Emulsion), and others.
• Age-related Vision Dysfunction Market Dynamics: Age-related Vision Dysfunction Market drivers and Age-related Vision Dysfunction Market Barriers
• Age-related Vision Dysfunction Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Age-related Vision Dysfunction Unmet Needs, KOL's views, Analyst's views, Age-related Vision Dysfunction Market Access and Reimbursement

Table of Content
1 Key Insights
2 Report Introduction
3 Executive Summary
4 Key Events
5 Epidemiology and Market Forecast Methodology
6 Age-related Vision Dysfunction Market Overview at a Glance
7 Disease Background and Overview of Age-related Vision Dysfunction
8 Treatment and Management
9 Epidemiology and Patient Population of Age-related Vision Dysfunction
10 Patient Journey
11 Marketed Drugs
12 Emerging Drugs
13. Age-related Vision Dysfunction: Seven Major Market Analysis
14 Unmet Needs
15 SWOT Analysis
16 KOL Views
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer

List of Top Selling Market Research Reports in 2024
Angio Suites Market- https://www.delveinsight.com/report-store/angio-suites-market
Clostridium Difficile Infections Market- https://www.delveinsight.com/report-store/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
Cone Rod Dystrophy Market- https://www.delveinsight.com/report-store/cone-rod-dystrophy-market
Congenital Heart Defect Devices Market- https://www.delveinsight.com/report-store/congenital-heart-defect-devices-market
Eosinophilic Disorder Market- https://www.delveinsight.com/report-store/eosinophilic-disorder-market
Friedreich's Ataxia Market- https://www.delveinsight.com/report-store/friedreichs-ataxia-market
Hyperphosphatemia Market- https://www.delveinsight.com/report-store/hyperphosphatemia-market
Inflammatory Pain Market- https://www.delveinsight.com/report-store/inflammatory-pain-market
Langerhans Cell Histiocytosis Market- https://www.delveinsight.com/report-store/langerhans-cell-histiocytosis-market
Myocardial Infarction Market- https://www.delveinsight.com/report-store/myocardial-infarction-market
Oral Electrolyte Solutions Market- https://www.delveinsight.com/report-store/oral-electrolyte-solutions-market
Attention Deficit Hyperactivity Disorder Market- https://www.delveinsight.com/report-store/attention-deficit-hyperactivity-disorder-adhd-market
Atopic Dermatitis Market- https://www.delveinsight.com/report-store/atopic-dermatitis-market
Adult T-Cell Leukemia Market- https://www.delveinsight.com/report-store/adult-t-cell-leukemia-lymphoma-market
Blastomycosis Market- https://www.delveinsight.com/report-store/blastomycosis-market
Gastroesophageal Junction Adenocarcinoma Market- https://www.delveinsight.com/report-store/gastroesophageal-junction-adenocarcinoma-market
Mantle Cell Lymphoma Market- https://www.delveinsight.com/report-store/mantle-cell-lymphoma-market
Post Operative Pain Management Market- https://www.delveinsight.com/report-store/post-operative-pain-management-market
Postoperative Pain Market- https://www.delveinsight.com/report-store/postoperative-pain-market
Prostate Cancer Market- https://www.delveinsight.com/report-store/prostate-cancer-market-insight
Transmucosal Drug Delivery Devices Market- https://www.delveinsight.com/report-store/transmucosal-drug-delivery-devices-market
Trauma Fixation Devices Market- https://www.delveinsight.com/report-store/trauma-devices-market
Restless Legs Syndrome Market- https://www.delveinsight.com/report-store/restless-legs-syndrome-market

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Contact Us
Yash Bhardwaj
info@delveinsight.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Age-related Vision Dysfunction Market Size is expected to grow by 2034, estimates DelveInsight here

News-ID: 3627548 • Views:

More Releases from DelveInsight Business Research LLP

Genital Warts Pipeline Insights Report 2025 | DelveInsight
Genital Warts Pipeline Insights Report 2025 | DelveInsight
DelveInsight's, "Genital Warts Pipeline Insight 2025" report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Genital Warts pipeline landscape. It covers the Genital Warts pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight and stay ahead
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
Traumatic Brain Injury Pipeline Drugs Report 2025 | DelveInsight
DelveInsight's "Traumatic Brain Injury Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Tthe raumatic Brain Injury pipeline landscape. It covers the Traumatic Brain Injury pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Traumatic Brain Injury pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
Bone Metastasis Pipeline Assessment Report 2025 | DelveInsight
DelveInsight's, "Bone Metastases Pipeline Insight, 2025," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Bone Metastases pipeline landscape. It covers the Bone Metastasis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Bone Metastasis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore the comprehensive insights by DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsight
Acquired Immunodeficiency Syndrome Treatment Market Size Report 2032 | DelveInsi …
DelveInsight's "Acquired Immunodeficiency Syndrome Market Insights, Epidemiology, and Market Forecast-2032′′ report offers an in-depth understanding of the Acquired Immunodeficiency Syndrome, historical and forecasted epidemiology as well as the Acquired Immunodeficiency Syndrome market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the Acquired Immunodeficiency Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Acquired Immunodeficiency Syndrome Market

All 5 Releases


More Releases for Vision

Contact Lens Solution Market Growth to Accelerate in Forecast Period (2025-2035) …
Industry Outlook The Contact Lens Solution Market accounted for USD 3.73 Billion in 2024 and is expected to reach USD 5.62 Billion by 2035, growing at a CAGR of around 3.8% between 2025 and 2035. The contact lens solution market includes entities developing and marketing products used to clean, disinfect, and store contact lenses. The right solutions serve two essential functions, including keeping contact lenses clean, prolonging their lifespan, and maintaining
Vision-Based Battery Quality Control Market Expected To Rise Significantly From …
"Worldwide Market Reports offers 𝐔𝐩𝐭𝐨 𝟕𝟎% 𝐝𝐢𝐬𝐜𝐨𝐮𝐧𝐭 on Vision-Based Battery Quality Control Market Reports on Single User Access and Unlimited User Access" The report discusses everything a marketer requires before investing in the global Vision-Based Battery Quality Control during the forecast period 2023-2030. It provides detailed insight into current trends, shares, size, and sales value and volume. The data used for this report is obtained from reliable industry sources, paid resources,
Machine Vision And Vision Guided Robotics Market Demand Analysis To 2027 Lead By …
The "Machine Vision And Vision Guided Robotics" Market report offers qualitative and quantitative insights and a detailed analysis of market size & growth rate for all possible segments in the market. The Global Machine Vision And Vision Guided Robotics Industry presents a market overview, product details, classification, and market concentration. The report also provides an in-depth survey of key players in the market which is based on various competitive intelligence
Machine Vision And Vision Guided Robotics Market 2021 Business Scenario – Cogn …
Global Machine Vision And Vision Guided Robotics Market Research Report 2021 The report begins with the overview of the Machine Vision And Vision Guided Robotics Market and offers throughout development. It presents a comprehensive analysis of all the regional and major player segments that gives closer insights upon present market conditions and future market opportunities along with drivers, trending segments, consumer behaviour, pricing factors and market performance and estimation. The forecast
Vision Care Market: VISION 2020 Initiative Boosts Stakeholders amid Growing Conc …
According to WHO, vision impairment is one of the major global issues as more than 1 billion people live with near vision or some sort of distance impairment. Getting eyeglasses prescriptions is specifically hard in developing countries given optometrists are located in urban areas and patients from rural areas get deprived of corrective treatment , as a result, people suffer from uncorrected impairments. WHO warns uncorrected impairments could lead to
Global Machine Vision and Vision Guided Robotics Market 2019 - Cognex, Teledyne …
The new market research study on Global Machine Vision and Vision Guided Robotics Market in-depth market analysis with specific segments such as application, regional markets, end-users, policy analysis, value chain structure, and emerging trends. The Machine Vision and Vision Guided Robotics market report makes a case for investments in particular regions based on a realistic view of their regulatory environment, manufacturing dynamics and availability of skills and resources.The report’s analysis